Welcome to our dedicated page for ZyVersa Therapeutics news (Ticker: ZVSA), a resource for investors and traders seeking the latest updates and insights on ZyVersa Therapeutics stock.
ZyVersa Therapeutics reports clinical-stage biopharmaceutical developments for renal and inflammatory diseases. Its updates center on Cholesterol Efflux Mediator™ VAR 200, a kidney-disease program that targets removal of excess renal lipids and has been associated with focal segmental glomerulosclerosis, diabetic kidney disease and Alport syndrome, and Inflammasome ASC Inhibitor IC 100, a program for chronic inflammation and cardiometabolic conditions associated with obesity.
Recurring company news also covers financial results, cash and financing activity, research publications related to kidney lipotoxicity and inflammasome biology, clinical or preclinical program updates, and the quotation of ZVSA common stock on the OTCQB Venture Market.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.